Selinexor for wilms tumor and other solid tumors
Treatments studied
Part of Brain & nervous system, Cancer, Genetic & congenital, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests a drug called selinexor for children and young adults with certain types of solid tumors (like Wilms tumor, rhabdoid tumors, MPNST, or others with specific genetic changes) that have come back or not responded to standard treatment. Participants take selinexor pills to see if it can shrink or control their cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 12 months or older
- Tumor type is one of: Wilms tumor, rhabdoid tumor, MPNST, or another solid tumor with evidence that selinexor might help, or a tumor with a BCOR gene change
- Has already had at least one type of cancer treatment that didn't work or stopped working
- Has not taken selinexor or a similar drug before
- Is well enough to be up and about (performance score of 60% or higher)
- Has adequate organ function (liver, kidneys, and blood counts checked by standard tests)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a drug called selinexor (taken by mouth) for people with myelofibrosis who have low to moderate platelet counts and haven't tried JAK inhibitors yet. It aims to shrink the spleen and improve symptoms.
This trial tests a combination of two drugs, selinexor and gemcitabine, for people with a type of soft-tissue sarcoma (leiomyosarcoma or malignant peripheral nerve sheath tumor) that has spread or cannot be surgically removed and has gotten worse despite at least one prior treatment. The goal is to see if this combination can help shrink or slow the cancer.
This trial tests the drug selinexor as a single treatment to lower very high blood cell counts or shrink an enlarged spleen in patients with certain chronic blood cancers (polycythemia vera, essential thrombocythemia, or primary myelofibrosis). It may be an option if standard treatments are not working or cause side effects.
This Phase 2 study tests whether a medicine called selinexor, combined with COPL, can shrink newly diagnosed NK/T-cell lymphoma that is advanced (stage III–IV). It also looks at how safely the treatment works in people who have good enough blood counts and organ function.
This program provides access to an experimental drug called selinexor for patients who have tried other treatments and have no other options. The goal is to give patients a chance to try this medication while it is still being studied.
This trial tests a combination of two drugs, selinexor and azacitidine, for people with high-risk blood cancers like acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS). The goal is to see if this combination can help control the disease, especially before a stem cell transplant.
Hear when a new Wilms Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.